A Phase III, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia

被引：0

作者：

Daver, Naval G. ^{[1
]}

Vyas, Paresh ^{[2
]}

Xing, Guan ^{[3
]}

Renard, Camille ^{[3
]}

Bagheri, Taravat ^{[3
]}

Curtis, Kelly ^{[3
]}

Sallman, David A. ^{[4
]}

Wei, Andrew H. ^{[5
,6
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Weatherall Inst Mol Med, Oxford, England

[3] Gilead Sci Inc, Foster City, CA USA

[4] Moffitt Ctr Canc, Tampa, FL USA

[5] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[6] Eliza Hall Inst Med Res, Melbourne, Vic, Australia

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

AML; magrolimab; azacitidine; ENHANCE-2; anti-CD47; Trial-in-Progress;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AML-554

引用

页码：S312 / S312

页数：1

共 50 条

[21] An open-label extension study of lurasidone safety and efficacy in patients with schizophrenia previously randomized to lurasidone or risperidone
Mattingly, G.
Tocco, M.
Cucchiaro, J.
Xu, J.
Loebel, A.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 147 - 147
[22] Trial in Progress: An Open Label Phase I/II, Multicenter Study Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a BCL-2 Inhibitor Combined with Azacitidine in Adults with Previously Untreated Acute Myeloid Leukemia Ineligible for Intensive Treatment
Pierola, Ana Alfonso
De Botton, Stephane
Jang, Jun Ho
Campbell, Victoria
O'Nions, Jenny
Calbacho, Maria
Ervin-Haynes, Annette L.
Keagle, Kristen
Maillard, Aline
Beneton, Maud
Romagnoli, Mathilde
Broniscer, Alberto
BLOOD, 2023, 142
[23] Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy
Wang, Eunice S.
Montesinos, Pau
Minden, Mark D.
Lee, Je-Hwan
Heuser, Michael
Naoe, Tomoki
Chou, Wen-Chien
Laribi, Kamel
Esteve, Jordi
Altman, Jessica K.
Havelange, Violaine
Watson, Anne-Marie
Patkowska, Elzbieta
Liu, Shufang
Wu, Ruishan
Philipose, Nisha
Hill, Jason E.
Gill, Stanley
Rich, Elizabeth Shima
Tiu, Ramon V.
BLOOD, 2021, 138
[24] High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
Jun Li
Qi Han
Yanqing Huang
Yanhui Wei
Jie Zi
Lidong Zhao
Zhimei Cai
Xuzhang Lu
Rong Xiao
Yanming Zhang
Xiaotian Yang
Hao Xu
Naitong Sun
Wanchuan Zhuang
Zhengdong Wu
Yuan Xia
Yanli Xu
Bin He
Wei Zhu
Fengling Min
Yongchun Chen
Banghe Ding
Peimin Shi
Jing Xie
Hua Tang
Zefa Liu
Bingzong Li
Yu Sun
Hongxia Qiu
Limin Duan
Elanora Dovat
Chunhua Song
Laszlo SzeKely
Sinisa Dovat
Zheng Ge
Blood Cancer Journal, 12
[25] High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
Li, Jun
Han, Qi
Huang, Yanqing
Wei, Yanhui
Zi, Jie
Zhao, Lidong
Cai, Zhimei
Lu, Xuzhang
Xiao, Rong
Zhang, Yanming
Yang, Xiaotian
Xu, Hao
Sun, Naitong
Zhuang, Wanchuan
Wu, Zhengdong
Xia, Yuan
Xu, Yanli
He, Bin
Zhu, Wei
Min, Fengling
Chen, Yongchun
Ding, Banghe
Shi, Peimin
Xie, Jing
Tang, Hua
Liu, Zefa
Li, Bingzong
Sun, Yu
Qiu, Hongxia
Duan, Limin
Dovat, Elanora
Song, Chunhua
SzeKely, Laszlo
Dovat, Sinisa
Ge, Zheng
BLOOD CANCER JOURNAL, 2022, 12 (10)
[26] Selinexor in Combination with Venetoclax and Azacitidine for Newly Diagnosed (ND) Unfit Acute Myeloid Leukemia (AML): A Multicenter, Open-Label Prospective Study
Yang, Li
Chen, Fangli
Liang, Hong
Bai, Yunsong
Wu, Wenzhong
Yan, Xiaojing
Ren, Jinhai
Li, Si
Yu, Yang
Tong, Laigen
Pan, Deng
Liu, Ligen
BLOOD, 2023, 142
[27] Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study
Xue, Feng
Zhou, Hu
Chen, Yun
Sun, Jing
Zeng, Xiaojing
Jin, Chenghao
Lei, Pingchong
Li, Zhenyu
Xi, Yaming
Sun, Lirong
Cui, Zhongguang
Zhao, Xielan
Yang, Linhua
Zhang, Bangshuo
Shen, Aizong
Wu, Runhui
Wang, Xiaolin
Liu, Ling
Wang, Yuhua
Sun, Lizhi
Xia, Yan
Mo, Weichuan
Yuan, Dong
Lou, Jiwei
Gan, Taiping
Hu, Chengli
Ling, Chen
Su, Hongsheng
Wang, Yali
Tang, Baolin
Yang, Renchi
BLOOD, 2022, 140 : 8468 - 8469
[28] AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.
Stein, Eytan
Dinardo, Courtney Denton
Jang, Jun Ho
Miyazaki, Yasushi
Martinez, Roberto Ovilla
Auer, Julia
Zhang, Vickie
Koralek, Daniel O.
Wu, Bin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib As Monotherapy and in Combination with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Ptaszynski, Mieke
Payton, Marie
Farrow, Marcia
Feldman, Eric
BLOOD, 2024, 144 : 6008 - 6009
[30] Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE) :an open-label, phase 2a dose-finding study
Salamero, Olga
Molero, Antonieta
Perez-Simon, Jose Antonio
Arnan, Montserrat
Coll, Rosa
Garcia-Avila, Sara
Acuna-Cruz, Evelyn
Cano, Isabel
Somervaille, Tim C. P.
Gutierrez, Sonia
Arevalo, Maria Isabel
Xaus, Jordi
Buesa, Carlos
Limon, Ana
Faller, Douglas, V
Bosch, Francesc
Montesinos, Pau
LANCET HAEMATOLOGY, 2024, 11 (07): : e487 - e498

← 1 2 3 4 5 →